NDAORALTABLET
Approved
Dec 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZAGAM (sparfloxacin) is an oral fluoroquinolone antibiotic approved in 1996 for treating bacterial infections, primarily respiratory tract and skin infections. It works by inhibiting bacterial DNA gyrase and topoisomerase IV, disrupting DNA replication in susceptible organisms. The drug is administered orally as a tablet for systemic infection management.
LOE Approaching
As a mature fluoroquinolone facing loss of exclusivity, ZAGAM likely operates with a lean commercial team focused on maintaining legacy revenue rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ZAGAM represents a career position in portfolio management and operational excellence rather than high-growth commercial development. Professionals should expect focus on efficiency, stakeholder management, and defending market position against generic and branded competitors.
Brand Manager (legacy portfolio management)Sales Representative (maintenance)
Worked on ZAGAM at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.